NEW YORK ( TheStreet) -- Shares of Cleveland BioLabs (Nasdaq: CBLI) were gapping down Friday morning with an open price 12.6% lower than Thursday's closing price. The stock closed at $4.45 Thursday and opened today's trading at $3.89. The average volume for Cleveland BioLabs has been 417,700 shares per day over the past 30 days. Cleveland BioLabs has a market cap of $135.6 million and is part of the services sector and diversified services industry. Shares are down 38.4% year to date as of the close of trading on Thursday. Cleveland Biolabs, Inc. engages in the discovery, development, and commercialization of products for cancer treatment and protection of normal tissues from radiation and other acute stresses. TheStreet Ratings rates Cleveland BioLabs as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and feeble growth in its earnings per share. You can view the full Cleveland BioLabs Ratings Report. Get more investment ideas from our investment research center. Interested in other stocks that are gapping down? Get free SMS text alerts sent to you when the action happens by texting DOWN to 95370 or select from multiple alert options.